Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (251)
  2. Journal Article (99)
  3. Research Letter (11)
  4. Review (7)
  5. Correspondence (3)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (375)
  2. Department of Medicine (375)
  3. Hematologic Malignancies Research (375)
  4. Hematologic Malignancies, Division of (375)
  5. Myeloma (375)
  6. Survivorship Research (221)

More Groups

People
  1. Hani Hassoun (199)
  2. Heather Landau (184)
  3. Sergio Giralt (182)
  4. David Chung (174)
  5. Neha Korde (170)
  6. Sham Mailankody (167)

More People

Years
  1. 2025 (6)
  2. 2024 (52)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (140)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (40)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (13)
  6. Blood Advances (11)

More Publications

Publishers
  1. American Society of Hematology (151)
  2. Elsevier Inc. (78)
  3. American Society of Clinical Oncology (40)
  4. Nature Publishing Group (24)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (13)

More Publishers

Results (375)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study
    Meeting Abstract

    Patel, K.; Zonder, J. A.; Sano, D.; Maris, M.; Lesokhin, A.; von Keudell, G.; Lai, C.; Ramchandren, R.; Catalano, T.; Lin, G. H. Y.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Updated results from CARTITUDE-1: Phase 1b/2study of ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Martin, T.; Usmani, S. Z.; Berdeja, J. G.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Hari, P.; Avigan, D.; Deol, A.; Htut, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The genomic landscape of Waldenström Macroglobulinemia reveals sustained germinal center activity and late-developing copy number aberrations
    Meeting Abstract

    Maclachlan, K. H.; Bagratuni, T.; Kastritis, E.; Ziccheddu, B.; Lu, S. X.; Yellapantula, V. D.; Famulare, C.; Diamond, B.; Chojnacka, M.; Raj, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Magnetismm-3: An open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Lesokhin, A.; Iida, S.; Stevens, D.; Gabayan, A. E.; Ma, W. D.; Sullivan, S.; Raab, M. S.
    Blood (2021)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience
    Meeting Abstract

    Hultcrantz, M.; Orozco, J.; Peterson, T. J.; Derkach, A.; Hassoun, H.; Korde, N.; Lu, S. X.; Mailankody, S.; Patel, D.; Shah, U. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Normalization of the immune microenvironment during lenalidomide maintenance is associated with sustained MRD negativity in patients with multiple myeloma
    Meeting Abstract

    Coffey, D. G.; Maura, F.; Gonzalez-Kozlova, E.; Diaz-Mejia, J.; Luo, P.; Zhang, Y.; Xu, Y.; Warren, E. H.; Smith, E. L.; Cho, H. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)
    Meeting Abstract

    Bahlis, N. J.; Raje, N. S.; Costello, C.; Dholaria, B. R.; Solh, M. M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Liu, F.; Liao, K. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients
    Meeting Abstract

    Hevroni, G.; Mastey, D.; Tavitian, E.; Derkach, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save